These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 23114751)

  • 1. Deregulated chromatin remodeling in the pathobiology of brain tumors.
    Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
    Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma epigenetics: novel mechanisms, markers, and medicines.
    Lee JJ; Murphy GF; Lian CG
    Lab Invest; 2014 Aug; 94(8):822-38. PubMed ID: 24978641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
    Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
    Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
    Herranz M; Esteller M
    Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting epigenetic regulations in cancer.
    Ning B; Li W; Zhao W; Wang R
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):97-109. PubMed ID: 26508480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Chromatin Remodeling for Cancer Therapy.
    Kaur J; Daoud A; Eblen ST
    Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic targets in cancer: the epigenetic connection.
    Herranz M; Esteller M
    Clin Transl Oncol; 2006 Apr; 8(4):242-9. PubMed ID: 16648099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule modulators of histone acetylation and methylation: a disease perspective.
    Selvi BR; Mohankrishna DV; Ostwal YB; Kundu TK
    Biochim Biophys Acta; 2010; 1799(10-12):810-28. PubMed ID: 20888936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
    Shaker S; Bernstein M; Momparler LF; Momparler RL
    Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of gene expression as an anticancer drug target.
    Ferguson LR; Tatham AL; Lin Z; Denny WA
    Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics in cancer: targeting chromatin modifications.
    Ellis L; Atadja PW; Johnstone RW
    Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
    Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
    Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.
    Venza I; Visalli M; Fortunato C; Ruggeri M; Ratone S; Caffo M; Caruso G; Alafaci C; Tomasello F; Teti D; Venza M
    Epigenetics; 2012 Nov; 7(11):1315-30. PubMed ID: 23051921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleosome remodeling and epigenetics.
    Becker PB; Workman JL
    Cold Spring Harb Perspect Biol; 2013 Sep; 5(9):. PubMed ID: 24003213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.